Skip to content
value.today

Bio Blast Pharma Ltd.

🇮🇱 Tel Aviv, Israel, IsraelPharmaceuticalsFounded 2012
Total raised
$11 M
2 rounds on record
Latest round
$7 M
Mar 2016
First round on record
Feb 2014
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Bio Blast Pharma Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2016$7 MNo. 2$2 to $10 million

Bio Blast Pharma Ltd.: Raise no. 2, Mar 2016

Investors in this round

4 investors had bought by the notice of Apr 1, 2016: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$469,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Colin Foster · Executive Officer, Director
  • Fredric Price · Executive Officer, Director
  • Leigh M. Cherry · Executive Officer
  • Paul Firuta · Executive Officer
  • Robert Cook · Executive Officer
  • Theresa M. Stevens · Executive Officer
  • Warren Wasiewski · Executive Officer
  • Dalia I. H. Megiddo · Director
  • Gili M. Cohen · Director
  • Isaac I. H. Krymolowski · Director
  • Marlene Haffner · Director
  • Michael M. Burshtine · Director
  • Ran Nusbaum · Director
  • Thomas I. H. Dubin · Director
  • Udi Gilboa · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Roth Capital Partners, LLC (CRD 15407) · Newport Beach, CaliforniaSold in NY
  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “The brokers are also entitled to an aggregate expense reimbursement of $35,000.”
  • On the amounts: “The warrants were issued in connection with an offering of (i) approximately 2.16 million ordinary shares issued in a registered direct offering, and (ii) unregistered warrants to purchase approximately 1.08 ordinary shares.”

Signed by Colin Foster, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 1, 2016. Read the notice at the SEC.

optionsSEC
Feb 2014$5 MNo. 1$2 to $10 million

Bio Blast Pharma Ltd.: Raise no. 1, Feb 2014

Investors in this round

28 investors had bought by the notice of Feb 13, 2014: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$332,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Dalia Megiddo · Executive Officer, Director
  • Udi Gilboa · Executive Officer, Director
  • Fredric Price · Director
  • Marlene Haffner · Director
  • Ran Nusbaum · Director
  • Yaron Daniely · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Aegis Capital Corp. (CRD 15007) · New York, New YorkSold in CA, CO, CT, FL, GA, IA, IL, MA, NC, NJ, NY, PA, TX

Signed by Dr. Dalia Megiddo, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 13, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Bio Blast Pharma Ltd. had no revenue when it filed its newest notice of a funding round (Apr 2016).

    SEC Form D (revenue range) · Apr 2016

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2016

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Bio Blast Pharma Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 28 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Bio Blast Pharma Ltd.
NameRoleNamed in
Colin FosterExecutive officerApr 2016
Fredric PriceExecutive officerApr 2016
Leigh M. CherryExecutive officerApr 2016
Paul FirutaExecutive officerApr 2016
Robert CookExecutive officerApr 2016
Theresa M. StevensExecutive officerApr 2016
Warren WasiewskiExecutive officerApr 2016
Dalia MegiddoExecutive officerFeb 2014
Udi GilboaExecutive officerFeb 2014
Colin FosterDirectorApr 2016
Dalia I. H. MegiddoDirectorApr 2016
Fredric PriceDirectorApr 2016
Gili M. CohenDirectorApr 2016
Isaac I. H. KrymolowskiDirectorApr 2016
Marlene HaffnerDirectorApr 2016
Michael M. BurshtineDirectorApr 2016
Ran NusbaumDirectorApr 2016
Thomas I. H. DubinDirectorApr 2016
Udi GilboaDirectorApr 2016
Dalia MegiddoDirectorFeb 2014
Yaron DanielyDirectorFeb 2014